Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NASDAQ:STAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.18+3.5%$1.20$0.64▼$2.92$47.60M-0.73512,391 shs25,007 shsSTABStatera Biopharma$0.00+100.0%$0.00$0.00▼$0.13$11K0.069,263 shs18,435 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-0.78%-7.32%-42.13%+40.74%-10.24%STABStatera Biopharma0.00%0.00%0.00%0.00%-83.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRNSBarinthus Biotherapeutics2.8569 of 5 stars3.53.00.00.02.40.81.3STABStatera BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 3.00Buy$3.00154.24% UpsideSTABStatera Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus Biotherapeutics$14.97M3.18N/AN/A$2.54 per share0.46STABStatera BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)STABStatera BiopharmaN/AN/A0.00∞N/AN/AN/AN/AN/ALatest STAB, BRNS, GWP, and SER EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A7.897.89STABStatera BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%STABStatera BiopharmaN/AInsider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics10.70%STABStatera Biopharma5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.34 million36.02 millionN/ASTABStatera Biopharma2053.30 millionN/ANot OptionableSTAB, BRNS, GWP, and SER HeadlinesRecent News About These CompaniesTivic Health receives two investigational new drug applications from StateraAugust 20 at 5:55 PM | msn.comBNP Paribas Primary New Issues: No STAB Notice - MorrisonsJuly 16, 2025 | globenewswire.comBNP Paribas Primary New Issues: No STAB Notice - NextureJuly 16, 2025 | globenewswire.comStatera Biopharma Inc. Stock Grades | STAB - Barron'sJuly 15, 2025 | barrons.comFed-up Minnesotans warn Tim Walz uses Midwest charm to drive far-left policies: ‘He will stab you in the back’August 10, 2024 | nypost.comNThe Scientific and Technical Advisory BodyMay 22, 2024 | unesco.orgUDog-walking NY couple turns table on would-be mugger who was hospitalized with stab wounds: videoMay 19, 2024 | foxnews.comPocket Bravery developer Statera Studio announces 2D platform fighter Shield Strike for PCMay 18, 2024 | gematsu.comGBridgend: Wife begged ex-councillor to end stab attack - courtMay 8, 2024 | bbc.co.ukStatera BioPharma Inc Ordinary SharesApril 18, 2024 | morningstar.comMCRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICAApril 12, 2024 | finance.yahoo.comArrests after man found with serious stab injuriesApril 7, 2024 | bbc.comBPolice appeal after man found with stab injuriesApril 4, 2024 | bbc.comBAEON Biopharma Inc.February 25, 2024 | wsj.comMereo BioPharma Group PLC ADR (MREO)January 30, 2024 | investing.comCrookes curry house knife used to stab teenager to deathDecember 14, 2023 | bbc.comBLeeds stab death: Police name victim of Chapeltown attackDecember 9, 2023 | bbc.comBTwo boys, 12, in court charged with Wolverhampton stab murderNovember 25, 2023 | bbc.co.ukWolverhampton: Two boys, 12, arrested over stab murder of manNovember 25, 2023 | bbc.co.ukARCA biopharma Inc ABIONovember 11, 2023 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?By Leo Miller | July 30, 2025Is PG&E an AI Power Play? Why Options Traders Are Betting BigBy Jeffrey Neal Johnson | August 2, 2025STAB, BRNS, GWP, and SER Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$1.18 +0.04 (+3.51%) Closing price 03:59 PM EasternExtended Trading$1.20 +0.02 (+1.69%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Statera Biopharma NASDAQ:STAB$0.0002 +0.00 (+100.00%) As of 01:27 PM EasternStatera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Rocket Lab Stock: Breakout Brewing or Time for Patience? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access